Stephens initiated coverage on Alpha Teknova
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Stephens initiated coverage of Alpha Teknova with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2025 | $8.00 | Overweight | Stephens |
| 2/10/2025 | $12.00 | Buy | Craig Hallum |
| 3/12/2024 | Buy → Neutral | BTIG Research | |
| 7/20/2021 | Overweight | Stephens | |
| 7/20/2021 | $27.00 | Overweight | Stephens & Co. |
| 7/20/2021 | Outperform | Cowen & Co. | |
| 7/20/2021 | $26.00 | Buy | BTIG |
10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
8-K - Alpha Teknova, Inc. (0001850902) (Filer)
EFFECT - Alpha Teknova, Inc. (0001850902) (Filer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4/A - Alpha Teknova, Inc. (0001850902) (Issuer)
4/A - Alpha Teknova, Inc. (0001850902) (Issuer)
Stephens resumed coverage of Alpha Teknova with a rating of Overweight and set a new price target of $8.00
Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00
BTIG Research downgraded Alpha Teknova from Buy to Neutral
Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p
First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef
Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p
First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and
SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)
SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)
SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)